Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.061 AUD | -4.69% | -1.61% | +38.64% |
Apr. 03 | Acrux, TruPharma Launch Dapsone 5% Gel in US | MT |
Feb. 29 | Transcript : Acrux Limited, H1 2024 Earnings Call, Feb 29, 2024 |
Sales 2024 * | 6.5M 4.23M | Sales 2025 * | 12.3M 8.01M | Capitalization | 17.73M 11.55M |
---|---|---|---|---|---|
Net income 2024 * | -3M -1.95M | Net income 2025 * | 2M 1.3M | EV / Sales 2024 * | 2.31 x |
Net cash position 2024 * | 2.7M 1.76M | Net cash position 2025 * | 5.2M 3.39M | EV / Sales 2025 * | 1.02 x |
P/E ratio 2024 * |
-4.69
x | P/E ratio 2025 * |
7.63
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.31% |
Latest transcript on Acrux Limited
1 day | -4.69% | ||
1 week | -1.61% | ||
Current month | +27.08% | ||
1 month | +24.49% | ||
3 months | -12.86% | ||
6 months | +48.78% | ||
Current year | +38.64% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Kotsanis
CEO | Chief Executive Officer | - | 14-11-02 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 21-06-20 |
Chief Tech/Sci/R&D Officer | - | 15-02-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Geoff Brooke
BRD | Director/Board Member | 68 | 16-05-31 |
Ross Dobinson
FOU | Founder | 72 | 97-12-31 |
Michael Kotsanis
CEO | Chief Executive Officer | - | 14-11-02 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 0.061 | -4.69% | 9 |
24-04-23 | 0.064 | +6.67% | 98,691 |
24-04-22 | 0.06 | 0.00% | 135,535 |
24-04-19 | 0.06 | +3.45% | 165,762 |
24-04-18 | 0.058 | -6.45% | 555,825 |
Delayed Quote Australian S.E., April 23, 2024 at 08:11 pm EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+38.64% | 11.51M | |
+18.96% | 42.78B | |
+18.59% | 22.25B | |
+13.01% | 14.39B | |
+11.84% | 13.55B | |
+35.40% | 11.27B | |
-9.80% | 6.95B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+6.29% | 5.01B |
- Stock Market
- Equities
- ACR Stock